Preliminary experience with pancreatic sphincterotomy as treatment for intraductal papillary mucinous neoplasm-associated recurrent pancreatitis

Background and study aims Pancreatic intraductal papillary mucinous neoplasms (IPMN) are cystic tumors of the pancreas characterized by a malignant potential. IPMN have been associated with recurrent pancreatitis (RP). Obstruction of the main pancreatic duct by thick mucus has been postulated to be...

Full description

Bibliographic Details
Main Authors: Laura Bernardoni, Stefano Francesco Crinò, Giorgia De Conti, Maria Cristina Conti Bellocchi, Nicolò De Pretis, Antonio Amodio, Luca Frulloni, Armando Gabbrielli
Format: Article
Language:English
Published: Georg Thieme Verlag KG 2017-11-01
Series:Endoscopy International Open
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-119753
_version_ 1818258850360328192
author Laura Bernardoni
Stefano Francesco Crinò
Giorgia De Conti
Maria Cristina Conti Bellocchi
Nicolò De Pretis
Antonio Amodio
Luca Frulloni
Armando Gabbrielli
author_facet Laura Bernardoni
Stefano Francesco Crinò
Giorgia De Conti
Maria Cristina Conti Bellocchi
Nicolò De Pretis
Antonio Amodio
Luca Frulloni
Armando Gabbrielli
author_sort Laura Bernardoni
collection DOAJ
description Background and study aims Pancreatic intraductal papillary mucinous neoplasms (IPMN) are cystic tumors of the pancreas characterized by a malignant potential. IPMN have been associated with recurrent pancreatitis (RP). Obstruction of the main pancreatic duct by thick mucus has been postulated to be the cause of pancreatitis. In a few isolated reports, pancreatic sphincterotomy (PS) has been reported to reduce the frequency of pancreatitis. The aim of this study was to assess the efficacy of PS in patients with IPMN-associated RP. Patients and methods We retrospectively identified patients with RP and IPMN who underwent PS from June 2010 to December 2015. Patients were included in two different groups: (a) main duct/mixed type IPMN (MD-IPMN) and (b) branch duct IPMN (BD-IPMN) with or without worrisome features/high risk stigmata. Other causes of RP were excluded. The number of pancreatitis episodes occurring during a comparable time period before and after PS was evaluated. Results In total, 16 patients were analyzed (seven included in the MD-IPMN group and nine in the BD-IPMN group). The numbers of pancreatitis episodes occurring before and after PS were 3.5 ± 2.32 and 0.56 ± 1.03, respectively (P < 0.0001). Mean follow-up was 27.4 months (range 6 – 63 months). Complete, partial (reduction of pancreatitis episodes > 50 %), and no response were obtained in 11 (68.7 %), 3 (18.7 %), and 2 patients (12.5 %), respectively. One (6.25 %) case of mild post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis was observed. No cancer was detected in resected patients. None of the BD-IPMN group patients had or developed worrisome features/high risk stigmata during follow-up. Conclusions PS seems to be effective in reducing the number of episodes of IPMN-associated pancreatitis and should be considered as a treatment option in selected clinical settings. However, active surveillance should be continued considering the malignant potential of IPMN. Further prospective controlled studies are needed to confirm our results.
first_indexed 2024-12-12T18:06:06Z
format Article
id doaj.art-a01a1dca3f764fa9baef165bbd1fe4a8
institution Directory Open Access Journal
issn 2364-3722
2196-9736
language English
last_indexed 2024-12-12T18:06:06Z
publishDate 2017-11-01
publisher Georg Thieme Verlag KG
record_format Article
series Endoscopy International Open
spelling doaj.art-a01a1dca3f764fa9baef165bbd1fe4a82022-12-22T00:16:29ZengGeorg Thieme Verlag KGEndoscopy International Open2364-37222196-97362017-11-010511E1144E115010.1055/s-0043-119753Preliminary experience with pancreatic sphincterotomy as treatment for intraductal papillary mucinous neoplasm-associated recurrent pancreatitisLaura Bernardoni0Stefano Francesco Crinò1Giorgia De Conti2Maria Cristina Conti Bellocchi3Nicolò De Pretis4Antonio Amodio5Luca Frulloni6Armando Gabbrielli7Gastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, University of Verona, G.B. Rossi University Hospital, Verona, ItalyGastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, University of Verona, G.B. Rossi University Hospital, Verona, ItalyGastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, University of Verona, G.B. Rossi University Hospital, Verona, ItalyGastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, University of Verona, G.B. Rossi University Hospital, Verona, ItalyGastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, University of Verona, G.B. Rossi University Hospital, Verona, ItalyGastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, University of Verona, G.B. Rossi University Hospital, Verona, ItalyGastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, University of Verona, G.B. Rossi University Hospital, Verona, ItalyGastroenterology and Digestive Endoscopy Unit, The Pancreas Institute, University of Verona, G.B. Rossi University Hospital, Verona, ItalyBackground and study aims Pancreatic intraductal papillary mucinous neoplasms (IPMN) are cystic tumors of the pancreas characterized by a malignant potential. IPMN have been associated with recurrent pancreatitis (RP). Obstruction of the main pancreatic duct by thick mucus has been postulated to be the cause of pancreatitis. In a few isolated reports, pancreatic sphincterotomy (PS) has been reported to reduce the frequency of pancreatitis. The aim of this study was to assess the efficacy of PS in patients with IPMN-associated RP. Patients and methods We retrospectively identified patients with RP and IPMN who underwent PS from June 2010 to December 2015. Patients were included in two different groups: (a) main duct/mixed type IPMN (MD-IPMN) and (b) branch duct IPMN (BD-IPMN) with or without worrisome features/high risk stigmata. Other causes of RP were excluded. The number of pancreatitis episodes occurring during a comparable time period before and after PS was evaluated. Results In total, 16 patients were analyzed (seven included in the MD-IPMN group and nine in the BD-IPMN group). The numbers of pancreatitis episodes occurring before and after PS were 3.5 ± 2.32 and 0.56 ± 1.03, respectively (P < 0.0001). Mean follow-up was 27.4 months (range 6 – 63 months). Complete, partial (reduction of pancreatitis episodes > 50 %), and no response were obtained in 11 (68.7 %), 3 (18.7 %), and 2 patients (12.5 %), respectively. One (6.25 %) case of mild post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis was observed. No cancer was detected in resected patients. None of the BD-IPMN group patients had or developed worrisome features/high risk stigmata during follow-up. Conclusions PS seems to be effective in reducing the number of episodes of IPMN-associated pancreatitis and should be considered as a treatment option in selected clinical settings. However, active surveillance should be continued considering the malignant potential of IPMN. Further prospective controlled studies are needed to confirm our results.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-119753
spellingShingle Laura Bernardoni
Stefano Francesco Crinò
Giorgia De Conti
Maria Cristina Conti Bellocchi
Nicolò De Pretis
Antonio Amodio
Luca Frulloni
Armando Gabbrielli
Preliminary experience with pancreatic sphincterotomy as treatment for intraductal papillary mucinous neoplasm-associated recurrent pancreatitis
Endoscopy International Open
title Preliminary experience with pancreatic sphincterotomy as treatment for intraductal papillary mucinous neoplasm-associated recurrent pancreatitis
title_full Preliminary experience with pancreatic sphincterotomy as treatment for intraductal papillary mucinous neoplasm-associated recurrent pancreatitis
title_fullStr Preliminary experience with pancreatic sphincterotomy as treatment for intraductal papillary mucinous neoplasm-associated recurrent pancreatitis
title_full_unstemmed Preliminary experience with pancreatic sphincterotomy as treatment for intraductal papillary mucinous neoplasm-associated recurrent pancreatitis
title_short Preliminary experience with pancreatic sphincterotomy as treatment for intraductal papillary mucinous neoplasm-associated recurrent pancreatitis
title_sort preliminary experience with pancreatic sphincterotomy as treatment for intraductal papillary mucinous neoplasm associated recurrent pancreatitis
url http://www.thieme-connect.de/DOI/DOI?10.1055/s-0043-119753
work_keys_str_mv AT laurabernardoni preliminaryexperiencewithpancreaticsphincterotomyastreatmentforintraductalpapillarymucinousneoplasmassociatedrecurrentpancreatitis
AT stefanofrancescocrino preliminaryexperiencewithpancreaticsphincterotomyastreatmentforintraductalpapillarymucinousneoplasmassociatedrecurrentpancreatitis
AT giorgiadeconti preliminaryexperiencewithpancreaticsphincterotomyastreatmentforintraductalpapillarymucinousneoplasmassociatedrecurrentpancreatitis
AT mariacristinacontibellocchi preliminaryexperiencewithpancreaticsphincterotomyastreatmentforintraductalpapillarymucinousneoplasmassociatedrecurrentpancreatitis
AT nicolodepretis preliminaryexperiencewithpancreaticsphincterotomyastreatmentforintraductalpapillarymucinousneoplasmassociatedrecurrentpancreatitis
AT antonioamodio preliminaryexperiencewithpancreaticsphincterotomyastreatmentforintraductalpapillarymucinousneoplasmassociatedrecurrentpancreatitis
AT lucafrulloni preliminaryexperiencewithpancreaticsphincterotomyastreatmentforintraductalpapillarymucinousneoplasmassociatedrecurrentpancreatitis
AT armandogabbrielli preliminaryexperiencewithpancreaticsphincterotomyastreatmentforintraductalpapillarymucinousneoplasmassociatedrecurrentpancreatitis